## 1H-benzimidazole-5,6-diamine: A Versatile Building Block for Research
1H-benzimidazole-5,6-diamine is a **heterocyclic organic compound** with the molecular formula C7H9N3. It's essentially a benzimidazole ring with two amine groups (NH2) attached at positions 5 and 6.
**Why is it important for research?**
1H-benzimidazole-5,6-diamine is a valuable starting material and building block in various research fields due to its **versatility and potential for diverse applications**:
* **Pharmaceutical Research:**
* **Anti-cancer Activity:** The compound has shown promise as a potential anti-cancer agent. Its ability to inhibit the growth of cancer cells has been studied in different cancer types, including leukemia and breast cancer.
* **Antimicrobial Activity:** Benzimidazole derivatives, including 1H-benzimidazole-5,6-diamine, have exhibited antimicrobial properties against a wide range of bacteria and fungi.
* **Anti-inflammatory Activity:** The compound has demonstrated potential anti-inflammatory effects, offering promise in treating various inflammatory conditions.
* **Materials Science:**
* **Organic Electronics:** Benzimidazole derivatives, particularly those with amine groups, can be incorporated into organic electronic materials. These materials are used in applications like organic light-emitting diodes (OLEDs) and organic solar cells.
* **Polymer Synthesis:** 1H-benzimidazole-5,6-diamine can serve as a monomer for the synthesis of various polymers, which can find uses in different fields like biomedicine and materials science.
* **Dye and Pigment Development:** The compound can be used as a starting material for the synthesis of various dyes and pigments with applications in textiles, printing, and coloring materials.
**Key Properties:**
* **Reactivity:** The amine groups on 1H-benzimidazole-5,6-diamine make it highly reactive, enabling it to undergo various chemical transformations, leading to diverse derivatives with tailored properties.
* **Optical Properties:** Benzimidazole derivatives often exhibit interesting optical properties, like fluorescence and phosphorescence, which are crucial for various applications in imaging, sensing, and lighting.
**Overall, 1H-benzimidazole-5,6-diamine is a highly versatile compound with significant potential for research in diverse fields like pharmaceutical development, materials science, and organic chemistry.** Its unique properties and reactivity make it an attractive starting material for the development of novel compounds with promising applications.
**Note:** It's important to remember that research is ongoing and the specific applications and potential of 1H-benzimidazole-5,6-diamine are still under investigation.
ID Source | ID |
---|---|
PubMed CID | 2773193 |
CHEMBL ID | 1589385 |
CHEBI ID | 107392 |
SCHEMBL ID | 4370465 |
SCHEMBL ID | 5270917 |
Synonym |
---|
EU-0010117 |
LS-12758 |
HMS2639F10 |
OPREA1_248651 |
MLS000724043 , |
smr000305638 |
1h-benzimidazole-5,6-diamine |
CHEBI:107392 |
AKOS000365695 |
FT-0666353 |
A837115 |
71209-21-7 |
1h-benzo[d]imidazole-5,6-diamine |
HMS3364E08 |
5,6-diaminobenzimidazole trihydrochloride |
SJVPHAOWYMKBPE-UHFFFAOYSA-N |
5,6-diamino-1h-benzo[d]imidazole |
5,6-diaminobenzimidazole |
SCHEMBL4370465 |
CHEMBL1589385 |
SCHEMBL5270917 |
bdbm34936 |
(6-amino-1h-benzimidazol-5-yl)amine |
cid_2773193 |
Q27185699 |
1h-1,3-benzodiazole-5,6-diamine |
D95042 |
CS-0117064 |
DTXSID201327877 |
EN300-1588743 |
Class | Description |
---|---|
benzimidazoles | An organic heterocyclic compound containing a benzene ring fused to an imidazole ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 44.6684 | 0.0032 | 45.4673 | 12,589.2998 | AID2572 |
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 79.4328 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 0.4456 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 50.1187 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 2.2983 | 0.1259 | 19.1169 | 125.8920 | AID2549; AID2708 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 15.1014 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 1.1220 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
WRN | Homo sapiens (human) | Potency | 56.2341 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 11.5774 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
USP1 protein, partial | Homo sapiens (human) | Potency | 44.6684 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
TDP1 protein | Homo sapiens (human) | Potency | 24.5192 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 18.2563 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 28.1838 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 17.7828 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.5406 | 17.6392 | 96.1227 | AID2528 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
snurportin-1 | Homo sapiens (human) | Potency | 39.8107 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 95.2834 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 19.9526 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
geminin | Homo sapiens (human) | Potency | 9.2000 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
Glutamate receptor 1 | Rattus norvegicus (Norway rat) | Potency | 44.6684 | 0.0141 | 8.6024 | 39.8107 | AID2572 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 44.6684 | 0.0015 | 51.7393 | 15,848.9004 | AID2572 |
Glutamate receptor 3 | Rattus norvegicus (Norway rat) | Potency | 44.6684 | 0.0141 | 8.6024 | 39.8107 | AID2572 |
Glutamate receptor 4 | Rattus norvegicus (Norway rat) | Potency | 44.6684 | 0.0141 | 8.6024 | 39.8107 | AID2572 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Mcl-1 | Homo sapiens (human) | IC50 (µMol) | 54.0000 | 0.4000 | 7.1344 | 54.0000 | AID1417 |
MPI protein | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.1900 | 13.8256 | 50.1000 | AID1220 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
mitogen-activated protein kinase kinase kinase kinase 2 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 8.3150 | 0.6700 | 8.5344 | 26.3600 | AID1895; AID1897 |
mitogen-activated protein kinase kinase kinase 3 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 7.8700 | 2.6800 | 6.6700 | 11.8600 | AID1896 |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | EC50 (µMol) | 10.7400 | 0.0054 | 3.2510 | 20.9400 | AID1897 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Glutamate receptor 1 | Rattus norvegicus (Norway rat) |
plasma membrane | Glutamate receptor 2 | Rattus norvegicus (Norway rat) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |